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Abstract
Background We previously showed the practical and eth-
ical feasibility of using [14C]-microdosing for pharma-
cokinetic studies in children. We now aimed to show that
this approach can be used to elucidate developmental
changes in drug metabolism, more specifically, glu-
curonidation and sulfation, using [14C]paracetamol (AAP).
Methods Infants admitted to the intensive care unit
received a single oral [14C]AAP microdose while receiving
intravenous therapeutic AAP every 6 h. [14C]AAP phar-
macokinetic parameters were estimated. [14C]AAP and
metabolites were measured with accelerator mass spec-
trometry. The plasma area under the concentration-time
curve from time zero to infinity and urinary recovery ratios
were related to age as surrogate markers of metabolism.
Results Fifty children [median age 6 months (range 3
days–6.9 years)] received a microdose (3.3 [2.0–3.5] ng/kg;
64 [41–71] Bq/kg). Plasma [14C]AAP apparent total
clearance was 0.4 (0.1–2.6) L/h/kg, apparent volume of
distribution was 1.7 (0.9–8.2) L/kg, and the half-life was
2.8 (1–7) h. With increasing age, plasma and urinary AAP-
glu/AAP and AAP-glu/AAP-sul ratios significantly
increased by four fold, while the AAP-sul/AAP ratio sig-
nificantly decreased.
Conclusion Using [14C]labeled microdosing, the effect of
age on orally administered AAP metabolism was success-
fully elucidated in both plasma and urine. With minimal
burden and risk, microdosing is attractive to study devel-
opmental changes in drug disposition in children.
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Key Points
Information gaps still remain on drug metabolism in
children, especially on phase II metabolism. Drug
metabolism phenotyping studies in children present
ethical challenges inherent to risks related to
potential toxic effects of the phenotyping probe.
[14C]-Microdosing is feasible to phenotype drug
metabolism in children. We show a significant
decrease in the relative extent of paracetamol
sulfation and confirm an increase in glucuronidation
in the first 6 years of life after a single oral dose
administration.
Microdosing appears a promising tool to overcome
ethical barriers to study the ontogeny of drug
metabolism, and potentially, also other drug
disposition pathways in children. This may aid to a
better understanding of developmental
pharmacology to enable age-appropriate dosing for
ultimately effective and safe pharmacotherapy.
1 Introduction
Drug disposition in children may differ largely from that in
adults owing to age-related changes in drug absorption,
distribution, metabolism, and excretion [1, 2]. Drug meta-
bolism is one of the main determinants of variation in drug
disposition. While several knowledge gaps on the ontogeny
of drug-metabolizing enzymes have already been eluci-
dated (e.g., cytochrome P450 3A family) much is still
unknown, especially on the ‘phase II’ drug-metabolizing
enzymes [3, 4].
Phenotyping studies can be used to elucidate in vivo
drug metabolism pathways but in the pediatric population
these studies pose several challenges. For one, when a
validated phenotype probe for the pathway of interest is
available [5], it is often a marketed drug with potentially
therapeutic and toxic effects, which may not be accept-
able to ethics committees, physicians, parents, and their
children. Second, repeated blood sampling for pharma-
cokinetic analyses may be difficult in light of blood volume
limits (\5% of estimated circulating volume) and repeated
painful punctures. The alternative method, urinary sam-
pling, is technically challenging in young children espe-
cially without a urinary catheter and results often in
unreliable collections.
To overcome the risk associated with therapeutic or
toxic effects of a regular phenotype probe, microdosing
with carbon-14-labeled drugs may be an interesting
alternative [6–8]. A very low drug dose is not expected to
be toxic or result in any therapeutic effect. Additionally,
only very small blood volumes are needed for highly
sensitive analytical methods, such as accelerator mass
spectrometry (AMS) [9]. A microdose is defined as a
maximum of 100 lg or 1/100th of the no observed adverse
effect level or animal-based predicted pharmacologic dose
[10, 11]. Microdosing has been accepted by the US Food
and Drug Administration and European Medicines Agency
as a tool to study pharmacokinetics in adults [9]. If phar-
macokinetics show dose-linear behavior, pharmacokinetic
data can be extrapolated to therapeutic exposure [12–14].
Moreover, when a labeled oral dose is given simultane-
ously with a therapeutic intravenous dose (or routes
reversed), bioavailability can easily be determined, on the
condition that gastrointestinal dissolution, absorption, and
first-pass metabolism is proportional. The microdose is
then referred to as a microtracer. Two recent proof-of-
concept studies in a limited number of patients have shown
the ethical and practical feasibility of pediatric microdos-
ing/microtracer studies using [14C]paracetamol [13, 14].
Dose linearity was shown in adults for paracetamol (AAP)
from microdose to literature-reported therapeutic dose
under standard and inhibition conditions [15, 16]. Our own
proof-of-concept study supported the dose linearity of AAP
pharmacokinetics in children [13].
Paracetamol, also known as acetaminophen or N-acetyl-
p-aminophenol, is a common analgesic and antipyretic
agent. Its main metabolism pathways are glucuronidation
and sulfation. Glucuronidation occurs mainly via uridine
50-diphospho-glucuronosyltransferase (UGT) 1A1, 1A6,
1A9, and 2B15 and sulfation is catalyzed by sulfotrans-
ferase (SULT) 1A1, 1A3, 1A4, and 2A1 [17]. Although not
specific for individual enzymes, AAP pharmacokinetic
studies have provided valuable insight into the relative
contributions of glucuronidation and sulfation to the dis-
position of AAP. Paracetamol metabolism in young chil-
dren differs from that in adults. In neonates, a higher
proportion of urinary paracetamol sulfate than glucuronide
suggested immaturity of the involved UGTs, compensated
for by more mature sulfotransferases [18]. Other studies
showed a significant increase in the urinary paracetamol-
glucuronide (AAP-glu)/paracetamol-sulfate (AAP-sul)
ratio from 0.27 in 23-week-old preterm neonates to 0.75 in
3- to 9-year-old children and 2 in adults [19].
Despite these studies, gaps remain in the knowledge on
the ontogeny of AAP metabolism, especially for children
with bodyweights between 3 and 7 kg as well as between
25 and 50 kg [20, 21]. Most developmental changes in
drug-metabolizing enzymes occur in the first months of
life. Hence, a better insight into the exact pattern of the
age-related change in AAP metabolism may provide
valuable novel information. Moreover, studies on exclusive
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oral AAP and metabolite disposition are scarce, while
population pharmacokinetic studies using multiple cohorts
have often combined administration routes [20–22]. The
bioavailability of orally and rectally administered drugs
differs, hence phenotyping of combined small intestinal
and hepatic drug metabolism may be less precise [23].
Even though the oral bioavailability of AAP approaches
90% in adults, data in children are lacking and therefore a
contribution of intestinal metabolism on oral AAP dispo-
sition cannot be excluded (Tylenol Johnson & Johnson,
New Brunswick N.J., product information). Finally, most
studies used the urinary metabolite ratio as surrogate
marker for AAP metabolism. This method has limitations
owing to the difficult nature of complete and prolonged
urine collections in young children, with incomplete or
short collection intervals, and may have unexplained large
inter-individual variation reducing the power to detect
more subtle age-related variation.
Previously, we have shown that microdosing is practi-
cally and ethically feasible to study AAP pharmacokinetics
in children [13]. Now, using this innovative [14C]-micro-
dosing method, we aim to study the impact of age on the
disposition of orally administered AAP, over the age range
of 0–6 years. Plasma and urine analyses include metabo-
lites (AAP-glu, AAP-sul).
2 Methods
2.1 Subjects
Patients admitted to the pediatric intensive care unit of
the Erasmus MC-Sophia Children’s Hospital were con-
sidered for inclusion. Inclusion criteria were age from 0
through 6 years, medical need for intravenous AAP, an
indwelling arterial or central venous line in place, and
written informed consent from parents or legal guar-
dians. To reduce the impact of critical illness or bowel
disease on the pharmacokinetics of AAP, patients with
kidney and liver failure, more than one vasopressor drug,
inflammatory bowel disease, or who were intolerant to
enteral nutrition, or concomitantly receiving co-medica-
tion known to interact with AAP (according to
Micromedex, Truven Health Analytics Inc., Michi-
gan, www.micromedexsolutions.com) were excluded.
2.2 Study Design
The study design has been previously described in detail
[13]. The Dutch Central Committee on Research Involving
Human Subjects (The Hague) approved the study (Eu-
draCT 2011-005497-28). Purchase of [14C]AAP formula-
tion and radiopharmaceutical preparation have been
previously described [13]. A single [14C]AAP microdose
(3.3 ng/kg, 60 Bq/kg, 0.25 mL/kg) was given by mouth or
enteral feeding tube. The Dutch Nuclear Research and
Service Group estimated the radiation exposure of a single
microdose at\1 lSv and the exposure was explained to
parents/caregivers in relation to a continental flight ([4
lSv), medical imaging, or background radiation (2.5 lSv/
year in The Netherlands) [24]. The [14C]AAP oral dose
also contained 1.7 lg/kg non-labeled AAP, which is neg-
ligible in relation to the therapeutic intravenous dose and
considered irrelevant for pharmacokinetic estimations.
Enteral feeding tubes were flushed with 2 mL of saline to
ensure complete rinsing. Patients would receive the
[14C]AAP microdose as soon as the pump with the thera-
peutic intravenous AAP was started as part of clinical care,
dosed according to the Dutch Pediatric Handbook (http://
www.kinderformularium.nl): a 20-mg/kg loading dose,
followed by 10 mg/kg every 6 h (\1 month of age) or 15
mg/kg every 6 h (C1 month of age). The oral [14C]AAP
microdose would be given with the first or a sequential
AAP intravenous dose.
Blood samples (1.0 mL) were taken from the indwelling
catheter immediately before administration; at around 10
and 30 min; and at 1, 2, 4, 6, 12, and 24 h after dosing or
until the catheter was removed. After centrifuging, plasma
was stored at -80 C until analysis. Urine was collected in
patients who needed a urinary catheter for clinical reasons.
It was collected for a maximum 24 h or until the urinary
catheter was removed. Urine volume was entered by the
nurses in the clinical electronic patient record. One sample
(2 mL) was taken from the 24-h urine collection and stored
at -80 C until analysis.
2.3 Analytical Procedures
Previously, a method has been qualified to quantify
[14C]AAP, [14C]AAP-glu, and [14C]AAP-sul levels in
human plasma, using liquid chromatography in combina-
tion with AMS [13, 25]. The liquid chromatography plus
AMS qualification was performed in accordance with the
recommendation of the European Bioanalytical Forum
[26]. Qualification results are summarized in Mooij et al.
[13].
In short, the experimental outline was as follows; a
45-lL aliquot of plasma was extracted using 175 lL
methanol containing 6.6 lg/mL AAP, 8.10 lg/mL AAP-
glu, 10.0 lg/mL AAP-sul, and 6.6 lg/mL 3-acetami-
dophenol in 96-well protein precipitation plates. The pellet
was washed with 100 lL 0.9% NaCl: 100% methanol (1:4
v/v). The filtrates were combined and after evaporation,
redissolved in 30 lL 10 mM ammonium phosphate pH 3.4
(Eluent A). For each sample, 25 lL was injected on the
ultra performance liquid chromatography. Calibration
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standards at eight different levels, ranging from 0.4 to 180
Bq/L were prepared by spiking an [14C]AAP solution (SA
4100 Bq [14C]AAP/100 lg AAP) to blank pooled plasma.
Similarly, quality standards were prepared at three levels,
from 1.7 to 131 Bq/L. For the calibration and quality
standards, only 15 lL of the sample was used for extrac-
tion. Chromatographic conditions can be found in Table 1
of Mooij et al. [13]. The extraction recovery per sample
was determined by the area under the concentration-time
curve (AUC) of spiked AAP, AAP-glu, and AAP-sul vs.
the AUC of the corresponding compounds after a direct
injection of the extraction solution. The collected fractions
of AAP, AAP-glu, and AAP-sul were supplemented with
25 lg carbon-12, by adding 25 lL 1.97 mg/mL AAP.
Fractions were transferred to a tin foil cup and evaporated
to dryness prior to AMS analysis.
Urine samples were processed similarly, with a few
exceptions. Urine samples were diluted 20-fold with Mil-
liQ water prior to extraction. Like for plasma samples, 45
lL of the 20-fold diluted urine samples was extracted. The
extraction solution was spiked with 6.6 lg/mL
3-acetamidophenol only, which was used as an internal
standard to determine the recovery of the extraction. As
relatively high concentrations of cold AAP, AAP-glu, and
AAP-sul were present in urine samples owing to the ther-
apeutic dose the patients received; recoveries could not be
determined from spiked AAP, AAP-glu, and AAP-sul.
Each analytical run included the duplicate analysis of the
calibrators and triplicate analysis of quality standards, and
passed based on the acceptance criteria [26].
Tin foil cups were combusted on an elemental analyzer
(Vario Micro; Elementar, Langenselbold, Germany).
Generated CO2 was transferred to a home-built gas inter-
face, composed of a zeolite trap and syringe [25]. CO2
adsorbed to the trap on the interface; after heating of the
trap, the CO2 was transferred to a vacuum syringe using
helium. A final CO2/helium mixture of 6% was directed to
the AMS ion source, at a pressure of 1 bar and a flow of 60
lL/min. A 1-MV Tandetron AMS (High Voltage Engi-
neering Europe B.V., Amersfoort, The Netherlands) [27]
was used. The lower limit of quantification (LLOQ) of the
method was 0.58 Bq/L.
Table 1 Patient demographics
Age group 1
(birth–1 month)
Age group 2 (1
month–6 months)
Age group 3 (6
months–2 years)
Age group 4 (2
years–6 years)
Number 9 15 14 12
Postnatal age in weeks 0 (0–1) 23 (7–25) 35 (26–98) 197 (112–361)
Gestational age at birth in weeks 38.1 (34.9–40.7) 39.8 (33.1–42) 39.9 (30–41.7) 40 (36–40)
Weight (kg) 3 (2–3.5) 7 (3.5–9.2) 7.5 (6.1–12.8) 16.1 (12.9–25)
Weight (z-score) -1.12 (-2.1 to
0.1)
-0.63 (-2.5 to 1.5) -1.3 (-2.5 to 0.9) -0.02 (-2.9 to 2.1)
Gender (M/F) 8/1 14/1 10/4 9/3
Ethnicity (Caucasian/African/Asian/Other) 5/1/2/1 11/1/1/2 12/0/0/2 11/0/0/1
Reason for admission (surgical/medical) 8/1 12/3 12/2 6/6
Mechanical ventilation at start study (yes/no) 1/8 0/15 0/14 0/12
Enteral/tube feeding (yes/no) 3/6 10/5 9/5 6/6
PELOD score (on the study day) 11 (0–11) 10 (0–30) 6.5 (0–30) 10 (1–20)
Number of organs with dysfunction (on the study
day)
2 (0–2) 1 (0–3) 2 (0–3) 1 (1–3)
PRISM score 16 (0–31) 18 (4–41) 17 (0–34) 6 (0–44)
PIM score (%) 4 (0–20) 1 (0–10) 0 (0–9) 2 (0–33)
PIM II score (%) 5 (1–15) 0 (0–17) 0 (0–6) 1 (0–29)
Paracetamol dosing
[14C]AAP dose (ng) 9.8 (6.5–11.7) 22.8 (11.7–29.9) 23.4 (15.6–41.6) 52 (41.6–81.2)
[14C]AAP dose (Bq) 209 (125–228) 472 (235–639) 477 (313–890) 1035 (833–1594)
[14C]AAP dose normalized (mg/kg)
(dose 9 5E6)/weight)
15.6 (16.3–17.3) 16.2 (16.07–17) 16.3 (10–16.7) 16.3 (16.1–16.7)
Microdose administration via (oral/gastric
tube/duodenal tube/gastrostomy)
0/6/1/0 6/4/2/0 3/6/1/0 1/3/4/2
Medians and ranges
AAP paracetamol, PELOD pediatric logistic organ dysfunction, Number of organs with dysfunction numbers of organs scoring at least one in the
PELOD score, PRISM pediatric risk of mortality, PIM pediatric index of mortality
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2.4 Pharmacokinetic Analysis
The maximal concentration of [14C]AAP in plasma (Cmax)
and time to reach Cmax (Tmax) were extracted from the
plasma concentration vs. time curve. The AUC from time
zero to the last sampling time point (AUC0–t) was calcu-
lated using the log-linear trapezoidal method. The samples
below the LLOQ were set on 0.29 Bq/L (1/2 9 LLOQ).
The apparent volume of distribution (Vss) and total plasma
clearance (CL) were calculated by using standard non-
compartmental techniques. Pharmacokinetic parameters of
[14C]AAP-glu and [14C]AAP-sul were determined as
described above for [14C]AAP. All pharmacokinetic
parameters derived from individual patients were estimated
using the Excel PKsolver add-in software [28].
The plasma AUC from time zero to infinity (AUC0–inf)
and urinary recovery ratios of [14C]AAP-glu/[14C]AAP,
[14C]AAP-sul/[14C]AAP, and [14C]AAP-glu/[14C]-AAP-
sul were calculated to serve as ‘surrogate’ markers for
respectively glucuronidation and sulfation and their rela-
tive activity. Because AUC ratios were used for the pri-
mary outcomes, individual AUCs were not corrected for
individual dose. For clarity, the AUC0–inf ratios of
[14C]AAP-glu/[14C]AAP are denoted as ‘AAP-glu/AAP’
and the urinary recovery ratios are denoted as ‘U-AAP-glu/
U-AAP’.
Criteria for excluding study patients from all pharma-
cokinetic analyses were inadequate intake or too few blood
samples (fewer than four). If CL/F, Vss/F, or half-life (t1/2)
were not predicted because of non-negative estimated kz,
they were excluded for respectively CL/F, Vss/F, or t1/2
analyses. If the part of AUC0–inf that was extrapolated
beyond the last observation was larger than 20% of the
actual AUC0–t, then the AUC0–inf was excluded from the
analyses, as it would introduce unreliable overestimation of
the AUC0–inf.
2.5 Statistics
The [14C]AAP and metabolite concentrations were mea-
sured using Bq/L and converted to ng/L based on the exact
dose given (3.3 ng/kg contained 60 Bq/kg). For the
metabolites, Cmax was corrected for molecular weight
(AAP-glu/AAP 2.165 and AAP-sul/AAP 1.530). To com-
pare the disposition of oral [14C]AAP microdose to litera-
ture data of therapeutically dosed AAP, the microdose
concentrations were dose normalized to 15 mg/kg (as-
suming bioavailability is dose linear) by multiplying the
plasma [14C]AAP and metabolite concentrations (in ng/L)
by 5 9 106 [29].
Descriptive statistics of all variables are presented as
medians and ranges. Nonparametric Spearman’s rank cor-
relation was used to describe the relationship between
plasma and urinary metabolite ratios. Univariable linear
regression analyses were performed with postnatal age as
an independent variable and the pharmacokinetic parame-
ters (Cmax, Tmax, t1/2, AUC0–inf, weight-corrected CL/F, and
weight-corrected Vss/F), including the AUC ratios as
dependent variables. If necessary, dependent and inde-
pendent variables were log-transformed to ensure normal-
ity of the residuals and an adequate model fit. The Tmax was
compared between the different modes of oral adminis-
tration (oral, gastric/duodenal tube, or gastrostomy) using
the Kruskal–Wallis test. All statistical tests were two-sided
and used a significance level of p = 0.05.
3 Results
3.1 Patients
From 13 January, 2014 till 1 July, 2015, 50 patients (41
boys) with a median gestational age at birth of 40 (30–42)
weeks, and a median postnatal age of 6 months (3 days till
6 years and 11 months) participated in the study (Fig. 1;
Table 1). The main reason for admission was postsurgical
care (38 out of 50 patients). One patient needed mechanical
ventilation. Patients received one oral [14C]AAP microdose
(median [range]: 3.3 [2.0–3.5] ng/kg; 64 [41–71] Bq/kg)
and up to four intravenous AAP doses during the 24-h
study period as per clinical protocol. Variation in dose was
introduced by round-off errors and in one case a body-
weight error was found in the health record and rectified
after microdose administration leading to a dose of 2.0 ng/
kg, 41 Bq/kg. In some cases, the route of administration
was switched from intravenous to rectal for clinical reasons
after the microdose was given. In two cases, the blood
sampling was discontinued and excluded from the
232 eligible patients
AAP IV and access for blood sampling
114 patients approached
60 excluded
      22 <24 hours IC admission
      22 gastrointestinal disorder
      6 ECMO treatment
      4 unable to inform parents
      2 hepatic failure
      2 <24h arterial line
      1 renal failure
      1 anticipated death <48 hours
21 study drug not available
37 patient already participate in another study 
50 received [14C] AAP
48 completed study
64 refused to participate
2 vomited shortly after microdose intake; 
study ceased
Fig. 1 Flow chart of patient recruitment.AAP paracetamol, IC intensive
care, IV intravenous, ECMO extracorporeal membrane oxygenation
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pharmacokinetics analysis because the patient vomited
shortly after administration of the microdose, potentially
resulting in inadequate [14C]AAP intake. For nine patients,
the number of blood samples taken was too small (fewer
than four) to accurately estimate all pharmacokinetic
parameters and these patients were excluded from the
pharmacokinetics analysis. Of the 39 patients for the
[14C]AAP pharmacokinetics analysis, 19 received the
microdose [14C]AAP via a gastric tube, ten via oral
administration (in a buccal cavity), eight via a duodenal
tube, and two via gastrostomy. Three patients received
potentially interacting co-medication (phenytoin, pheno-
barbital, and pentobarbital) after administration of the
study drug for clinical reasons. For an additional patient,
AUC0–t, Cmax, and Tmax could be estimated but not CL/F,
Vss/F, and t1/2.
3.2 Pharmacokinetics
The exemplary plasma concentration-time curves for
[14C]AAP, [14C]AAP-glu, and [14C]AAP-sul of two indi-
vidual patients are depicted in Fig. 2. The pharmacokinetic
parameters are summarized in Table 2. The number of
samples below LLOQ were respectively 20 (8%), 41
(16%), and 33 (13%) for [14C]AAP, [14C]AAP-glu, and
[14C]AAP-sul of a total of 256 samples. Tmax for [
14C]AAP
was similar for all routes of administration, but with large
variability (Table 2). Cmax, weight-corrected Cl/F, and Vss/
F were also similar for all routes of administration and
similar between buccal and other administrations (gastric
tube, duodenal tube, or gastrostomy).
Dose-normalized (mg/kg dose) Cmax for [
14C]AAP,
[14C]AAP-glu, and [14C]AAP-sul were respectively, 8.4
(0.9–23.0) mg/L, 3.8 (0.4–16.0) mg/L, and 4.6
(0.5–20.5) mg/L. One outlier could be identified, but was
kept in the analysis; this patient had very low plasma
[14C]AAP and metabolite concentrations, even though no
abnormalities were noticed during oral dose administra-
tion. The patient may have partially spit out the buccally
given microdose.
3.3 Effect of Age on [14C]AAP Pharmacokinetics
and Metabolism
No significant relationship was detected between postnatal
age (which was log-transformed) and [14C]AAP Cmax,
Tmax, t1/2, AUC0–inf, weight-corrected CL/F, or weight-
corrected Vss/F. The AAP-glu/AAP ratio increased with
postnatal age (n = 35, R2 = 0.223, p\ 0.01) (Fig. 3a),
whereas the AAP-sul/AAP ratio decreased with postnatal
age (n = 36, R2 = 0.255, p\ 0.01) (Fig. 3b). Moreover,
the AAP-glu/AAP-sul ratio increased with age from 0.32 at
birth to 1.23 at the age of 6 years (n = 34, R2 = 0.456,
p\ 0.001) [Fig. 3c]. In these analyses, postnatal age and
all plasma and urine ratio outcomes were both log-trans-
formed. No significant differences were found in the AAP-
glu/AAP, AAP-sul/AAP, and AAP-glu/AAP-sul ratios
between the different routes of administration (respec-
tively, p = 0.6, p = 0.3, and p = 0.2).
Urine was collected reliably for at least 12 h (20.4 h
[11.8–28.5 h]) in 24 patients. Total median (range) urinary
recovery of [14C]AAP plus [14C]AAP-glu and [14C]AAP-
sul as the percentage of dose was 75% (28–99%). Recovery
of [14C]AAP, [14C]AAP-glu, and [14C]AAP-sul are shown
in Table 2. Percentage recovery of [14C]AAP-glu increased
with postnatal age (n = 24, R2 = 0.306, p\ 0.01);
[14C]AAP-sul recovery decreased with postnatal age
(n = 24, R2 = 0.175, p\ 0.05); while [14C]AAP recovery
remained stable with postnatal age (n = 24, R2 = 0.004,
p = 0.78). The percentage of total urinary [14C] recovery
([14C]AAP ? [14C]AAP-glu ? [14C]AAP-sul) was com-
puted for each individual separately. The percentage of
total urinary [14C] recovery also did not change with age
(n = 24, R2 = 0.003, p = 0.79).
The U-AAP-glu/U-AAP ratio significantly increased
with postnatal age (n = 24, R2 = 0.456, p\ 0.001)
(Fig. 4a), whereas the U-AAP-sul/U-AAP ratio showed a
borderline non-significant decrease with age (n = 24,
R2 = 0.150, p = 0.06) (Fig. 4b). The U-AAP-glu/U-AAP-
sul ratio increased linearly with postnatal age (n = 24,
R2 = 0.575, p\ 0.001) (Fig. 4c). A strong positive
Fig. 2 Two individual plots:
plasma concentration-time
curve AAP, AAP-glu, and AAP-
sul (Bq/L). AAP paracetamol,
AAP-glu paracetamol-
glucuronide, AAP-sul
paracetamol-sulfate
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correlation was found between the AAP-glu/AAP-sul and
U-AAP-glu/U-AAP-sul ratios (n = 17, r = 0.89,
p\ 0.001) (Fig. 5).
4 Discussion
Our study shows that [14C]-microdosing allows the study-
ing of age-related changes in drug metabolism in children,
using both plasma and urine as a matrix. Both the plasma
and the urine [14C]AAP glucuronide/sulfate ratios
increased approximately four fold with age (from 0 to 6
years), which may reflect the maturation of combined
intestinal and hepatic paracetamol glucuronidation and
sulfation.
Previously, pediatric studies have reported the AAP
pharmacokinetics after oral administration
[18, 21, 22, 30–32]. Our data, with average CL/F of 0.4
(0.1–2.6) L/h/kg and V/F of 1.7 (0.9–8.2 L/kg) are largely
in line with these studies. In a population pharmacokinetic
study combining the data of these studies [31, 33–36],
concerning more than 250 patients (mean age ± standard
deviation 11.8 ± 2.5 months) receiving oral and/or rectal
AAP, the mean CL/Foral was 0.2 L/h/kg (95% confidence
interval 0.16–0.23) [14.1 L/h/70 kg] and Vd/F was 1.12
L/kg (95% confidence interval 1.02–1.21) [78.7 L/70 kg]
[21]. Cl/F was 0.07 L/h/kg and V/F was 1.088 L/kg in a
‘post-hoc’ NONMEM analysis of a selection of 30 neo-
nates and infants (aged 1–90 days) [22]. The latter study
also found an age-related CL/F on pooled analyses of 221
children (aged 0–17 years). In contrast to this finding, we
did not find an effect of age on weight-corrected Cl/F, but
this might be explained by the small number of neonates in
our cohort or the absence of more complex exponential
functions to describe our data.
In our study, both the plasma and the urine AAP-glu/
AAP-sul ratio were related to age; the plasma ratio
increased from 0.32 in neonates to 1.23 in 6-year-old
children with a similar increase in urine. The AAP-glu/
AAP-sul ratio served as a surrogate marker for the relative
contribution of glucuronidation and sulfation to AAP
metabolism as in previous studies [18, 19, 21, 37]. Previous
Table 2 [14C]AAP pharmacokinetics
[14C]AAP [14C]AAP-glu [14C]AAP-sul
Plasma
AUC (0, t) (Bq/L h) 152 (24–462) (n = 39) 70 (9–339) (n = 39) 69 (8–576) (n = 39)
AUC (0, inf) (Bq/L h) 152 (25–489) (n = 38a) 75 (11–367) (n = 35a) 75 (9–597) (n = 37a)
CL/F (L/h) 3.1 (0.4–26.6) (n = 38) – –
CL/F (L/h/kg) 0.4 (0.1–2.6) (n = 38) – –
Vss/F (L) 11.1 (3.0–82.2) (n = 38) – –
Vss/F (L/kg) 1.7 (0.9–8.2) (n = 38) – –
t1/2 (h) 2.8 (1.0–7.0) (n = 38) – –
Cmax (Bq/L) 34.9 (3.8–89.6) (n = 39) 8.6 (0.8–38.1) (n = 39) 10.0 (1.1–41.0) (n = 39)
Cmax (ng/L) 1.7 (0.2–4.6) (n = 39) 0.9 (0.1–4.1) (n = 39) 0.8 (0.1–3.2) (n = 39)
Tmax (h) 1.0 (0.2–6.2) (n = 39) 4.1 (0.8–12.6) (n = 39) 3.0 (0.3–12.6) (n = 39)
Oral (n = 10) 2.0 (0.2–4.5) – –
Gastric tube (n = 19) 1.1 (0.2–7) – –
Duodenal tube (n = 8) 0.5 (0.3–2.4) – –
Gastrostomy (n = 2) 1.5 (0.3–2.7) – –
AUC(0, inf) ratio
AAP-glu/AAP
0.4 (0.1–1.6) (n = 35) – –
AUC(0, inf) ratio
AAP-sul/AAP
0.5 (0.2–1.4) (n = 36) – –
AUC(0, inf) ratio
AAP-glu/AAP-sul
1.1 (0.2–2.8) (n = 34) – –
Urine
Urinary recovery as percentage of [14C]AAP dose (%) 10 (4–17)% (n = 24) 29 (4–46)% (n = 24) 34 (12–74)% (n = 24)
Total urinary recovery as percentage of [14C]AAP dose (%) 75% (28–99%) (n = 24)
Medians and ranges
a Another 1, 4, and 2 patients were excluded from AUC0–inf analyses of respectively [
14C]AAP, [14C]AAP-glu, and [14C]AAP-sul, as the part of
the AUC0–inf that was extrapolated was larger than 20% of the AUC0–t
[14C]Paracetamol Microdosing to elucidate developmental changes in drug metabolism
studies reported changes in the urinary metabolites ratio
after oral AAP administration from 0.27 in 2- to 3-day-old
neonates, to 0.69 in 12-month-old infants, 0.81 in 2-year-
old infants, 0.75 in 3- to 9-year-old children, 1.61 in
12-year-old children to 1.8 in adults [18, 21, 30]. Limita-
tions of existing studies were: only reporting neonatal data
[30], or few patients aged less than 9 years [18] and a
combined cohort of oral and rectal administration, with
urinary data on AAP and metabolites (instead of plasma) of
15 patients with a small age range (11.8 ± 2.5 months)
[21]. To the latter study, an additional cohort of [200
children receiving oral and/or rectal AAP were added in the
AAP clearance analysis (without metabolite concentra-
tions). However, rectal AAP completely bypasses the small
intestine and partially bypasses the liver by draining in the
lower hemorrhoidal circulation. Consequently, metabolism
of rectally administered AAP does not optimally represent
the combined intestinal and hepatic glucuronidation and
sulfation activity.
Allegaert et al. showed in 23 preterm and term newborns
a significant increase of the urinary glucuronide/total drug
ratio with both increasing postnatal and postconceptional
age after intravenous administration of the pro-drug
propacetamol [38]. In 75 children (three neonates, 25
infants, 25 children, and 22 adolescents) who received
repeated intravenous AAP, glucuronidation was the pri-
mary pathway of elimination in the older, but not the
neonatal age group, where sulfation dominated [39]. The
urinary AAP-glu/AAP-sul ratio collected over 4 h after the
last dose, was low in neonates and higher at older age; 0.6
in neonates, 1.0 in infants, 1.4 in children, and 1.2 in
adolescents. First-pass drug metabolism after oral drug
administration may occur at both the intestine and the liver.
Here, we see similar ratio AAP-glu/AAP-sul data after oral
(our study) and intravenous administration (Zuppa et al.,
Allegaert et al.), which suggests that the intestinal contri-
bution to AAP metabolism or the ontogeny of intestinal
AAP metabolism either equals hepatic metabolism or is
negligible.
Exploring the maturation t1/2 of AAP-glu and AAP-sul
activities (Fig. 3), wemodeled a sigmoidal Emax curve for the
AAP-glu/AAP-sul ratio (results not shown). The wide confi-
dence intervals of the estimated parameters suggested low
evidence for a sigmoidal relationship. Visual inspection of the
a b
c
Fig. 3 a Increase of the plasma AAP-glu/AAP ratio with postnatal
age. b Decrease of the plasma AAP-sul/AAP ratio with increasing
age. c Increase of the plasma AAP-glu/AAP-sul ratio with postnatal
age. For linear regression analysis: plasma ratio and age were both
log-transformed. AAP paracetamol, AAP-glu paracetamol-glu-
curonide, AAP-sul paracetamol-sulfate, AUC0–inf area under the
concentration-time curve from time zero to infinity
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maturation curves suggests a quite sudden surge in glu-
curonidation after 200 days of age, but a more gradual
decrease in AAP sulfation from birth to 6 years of age.
Genetic polymorphisms are potentially an important
factor to explain inter-individual variability. A recent
review proposed several UGT polymorphisms that may
affect AAP disposition. To date, especially in children, no
polymorphism has proven to be clinically significant [40].
This study has several strengths. First, we show the
feasibility of a drug metabolism phenotyping study using
[14C]AAP with only 0.2 millionth of the therapeutic dose.
Although such a design has been used in adults, we now
show the feasibility to include a considerable number of
pediatric patients in the intensive care unit with a rich
blood sampling design and reliable urine collections. In
addition, this study provides cross-sectional data on both
the plasma and the urinary [14C]AAP metabolism after a
single oral dose administration in a continuous cohort from
3 days to 6 years of age. These data add to our under-
standing of the combined intestinal and hepatic glu-
curonidation and sulfation activities, which is of
importance given that most drugs are given orally. Another
strength is the combination of urine and plasma collection,
showing the feasibility of [14C]-microdosing to use either
matrix for drug metabolism phenotyping. The similar
developmental changes in plasma (this study) and urine
[30] suggest that both matrices can be used to study AAP
disposition. Plasma calculations were more reliable
a
c
b
Fig. 4 a Increase of the urinary recovery ratio AAP-glu/AAP with
postnatal age. b Urinary recovery ratio AAP-sul/AAP with postnatal
age. c Increase of the urinary recovery ratio AAP-glu/AAP-sul with
postnatal age. For linear regression analysis: urine ratio and age were
both log-transformed. AAP paracetamol, AAP-glu paracetamol-glu-
curonide, AAP-sul paracetamol-sulfate
Fig. 5 Correlation of the plasma AAP-glu/AAP-sul ratio and urinary
U-AAP-glu/U-AAP-sul ratio. AAP paracetamol, AAP-glu paraceta-
mol-glucuronide, AAP-sul paracetamol-sulfate, AUC0–inf area under
the concentration-time curve from time zero to infinity
[14C]Paracetamol Microdosing to elucidate developmental changes in drug metabolism
(n = 39 complete plasma collections vs. n = 24 complete
urine collections) with less variation compared with the
urinary recovery, but blood sampling is more invasive.
Hence, depending on the study population (with/without
indwelling arterial/venous access), age range, or renal
clearance-dependent drug, both plasma and urine could be
considered.
A possible barrier for investigators to use a [14C]-mi-
crodosing study in children is the perceived risk of radia-
tion [7]. To our own surprise, in this non-therapeutic study
with a radioactive-labeled probe, fear of radiation was
scarcely a reason for parents to withhold consent. Even
though drug studies in critically ill children in general are
challenging in obtaining parental consent [41], similar to
other studies on our intensive care unit, almost half of all
approached parents agreed to participate [42, 43]. Refusal
of consent was rather for reasons relating to the burden of
blood sampling or additional procedures. The PAMPER
consortium, also using [14C]AAP, experienced the same
inclusion rate [14].
A limitation of our study was that study patients did not
receive a single microdose exclusively and therefore one
could argue that it is not a ‘true’ microdosing study but a
microtracer study. We chose this design with the microdose
in addition to the same therapeutic drug because it was one
of the first microdosing studies in children, and it was
likely more acceptable to the ethics board and parents. We
are now convinced that this is not a major issue for parents,
who understood the concept of microdosing clearly and
realized it was associated with minimal burden for the
patient. Another limitation is the relatively low number of
neonates meeting inclusion criteria. Metabolites other than
AAP-glu and AAP-sul were not measured, and no con-
clusion can be made on the oxidation of AAP. Finally,
renal function was not taken into account in the analyses
using urinary ratios of the parent compound and metabolite
(U-AAP-glu/U-AAP and U-AAP-sul/U-AAP). These ratios
are indirect markers and might also reflect renal develop-
mental changes; therefore, our results may have underes-
timated the developmental change, as has been shown for
urinary markers for cytochrome P450 2D6 [44].
5 Conclusion
We show the feasibility of using a [14C]-drug microdose to
phenotype the ontogeny of drug metabolism in children.
The previously reported developmental change of parac-
etamol metabolism from mainly sulfation in neonates to
glucuronidation in older children was comparable. From
this study, plasma metabolite data were added on the
combined intestinal and hepatic pathways in a large pedi-
atric age range. The success of this study design is
promising for future studies on the development of drug
disposition.
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